Summary of currently available drugs which can be potentially used for treatment of COVID-19
The Table below was published in e-book International Pulmonologist’s Consensus On Covid-19 2nd ed 2020 on April 22nd 2020 (ed. Tinku
A forum for researchers, students and applicants in the field of cyclodextrin technology
The Table below was published in e-book International Pulmonologist’s Consensus On Covid-19 2nd ed 2020 on April 22nd 2020 (ed. Tinku
Set-up of an upcoming clinicl trial has been posted with the primary objectives of this study are to evaluate the
Israel approved on Tuesday the use of Gilead Sciences Inc’s antiviral drug remdesivir for the treatment of patients with COVID-19
In a pandemic like Covid-19 the urgent need excludes the development of new drugs, “conventional drug in new use” becomes
Gilead has signed non-exclusive voluntary licensing agreements with further generic pharmaceutical manufacturers based in Egypt and India to further expand supply
The Health Sciences Authority (HSA), in consultation with its Medicines Advisory Committee and infectious diseases experts informed healthcare professionals on
Bloombergs Businessweek published the story on how Gilead scineces prepared for the recently obtained emergency approval of the antiviral drug
Takeda Pharmaceutical Company Limited announced the results of the Phase 2 Pevonedistat-2001 trial. The study evaluated a cyclodextrin-enabled (SBECD) pevonedistat plus
Gilead Sciences, Inc. announced topline results from the Phase 3 SIMPLE trial in hospitalized patients with moderate COVID-19 pneumonia. This
As the readers of Cyclodextrin News have been already informed, 2020 BIO International Convention will be a digital event to